The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

M. O. Holmstrom; E. Martinenaite; S. M. Ahmad; O. Met; C. Friese; L. Kjaer; C. H. Riley; P. thor Straten; I. M. Svane; H. C. Hasselbalch; M. H. Andersen

doi:10.1038/leu.2017.214

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

M. O. Holmstrom, E. Martinenaite, S. M. Ahmad, O. Met, C. Friese, L. Kjaer, C. H. Riley, P. thor Straten, I. M. Svane, H. C. Hasselbalch, M. H. Andersen

Department of Clinical Medicine

47 Citations (Scopus)

Original language	English
Journal	Leukemia
Volume	32
Issue number	2
Pages (from-to)	429-437
ISSN	0887-6924
DOIs	https://doi.org/10.1038/leu.2017.214
Publication status	Published - 1 Feb 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2017.214

Cite this

@article{abde5b9cfb3f48df947df206d0514772,

title = "The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy",

author = "Holmstrom, {M. O.} and E. Martinenaite and Ahmad, {S. M.} and O. Met and C. Friese and L. Kjaer and Riley, {C. H.} and Straten, {P. thor} and Svane, {I. M.} and Hasselbalch, {H. C.} and Andersen, {M. H.}",

year = "2018",

month = feb,

day = "1",

doi = "10.1038/leu.2017.214",

language = "English",

volume = "32",

pages = "429--437",

journal = "Leukemia",

issn = "0887-6924",

publisher = "nature publishing group",

number = "2",

}

TY - JOUR

T1 - The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

AU - Holmstrom, M. O.

AU - Martinenaite, E.

AU - Ahmad, S. M.

AU - Met, O.

AU - Friese, C.

AU - Kjaer, L.

AU - Riley, C. H.

AU - Straten, P. thor

AU - Svane, I. M.

AU - Hasselbalch, H. C.

AU - Andersen, M. H.

PY - 2018/2/1

Y1 - 2018/2/1

U2 - 10.1038/leu.2017.214

DO - 10.1038/leu.2017.214

M3 - Journal article

C2 - 28676668

SN - 0887-6924

VL - 32

SP - 429

EP - 437

JO - Leukemia

JF - Leukemia

IS - 2

ER -

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

UN SDGs

Access to Document

Fingerprint

Cite this